Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

Cargando...
Miniatura

Fecha

Fecha

2020

Director de trabajo de grado

Título de la revista

Abrir versión en línea

ISSN de la revista

Título del volumen

Editor

JHEP Reports

Seleccione un documento PDF para visualizar

Resumen

During the early stages of the COVID-19 pandemic, EASL and ESCMID published a position paper to provide guidance for physicians involved in the care of patients with chronic liver disease. In the meantime, many countries and healthcare systems have been, or are still overwhelmed by the pandemic, significantly impacting on the care of this group of patients, whilst others have started to return towards their usual routine. In addition, many studies have been published focusing on how COVID-19 may affect the liver and how pre-existing liver diseases might influence the clinical course of COVID-19. While many aspects remain poorly understood, it has become increasingly evident that pre-existing liver diseases and liver injury during the course of the disease have to be kept in mind when caring for patients with COVID-19. Thus, this review should serve as an update on the previous position paper summarizing the evidence for liver disease involvement during COVID-19 and also provide some recommendations on how to return to routine care wherever possible.

Descripción

Palabras clave

ACE-I, Angiotensin-converting enzyme inhibitor, ACE2, Acute-on-chronic liver failure, ALT, Metabolic-dysfunction associated fatty liver disease

Citación

Aprobación

Revisión

Complementado por

Referenciado por